Drug intelligence / Profile preview

AER001

Development stage: Unknown
Lead developer: Aerium Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AER001 is a preclinical monoclonal antibody developed by Aerium Therapeutics for the prevention and treatment of COVID-19 and future pandemic threats. It is designed to neutralize SARS-CoV-2 variants by binding to the Receptor Binding Domain (RBD) of the viral Spike protein, thereby blocking viral attachment and entry into human cells.

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on AER001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AER001.

Explore the full profile